April/May #187 : HIV Docs Slow on Early Treatment - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


Recovering Your Life

Navigating Treatment as Prevention

From the Editor

High Hopes


Letters-April/May 2013


Positive Support

POZ Planet

Return to Sender

Old-School Kicks

My Bloody Valentine

Talk of the Town

Safe Sex 3.0

Bar None

Coming Attractions


What Would You Do?

Care and Treatment

The Heart of Cardiovascular Risks

E-Reminders Help Patient Outcomes

HIV Docs Slow on Early Treatment

TasP in the Real World

An Almost Normal Life Expectancy?

Research Notes

Prevention: Spinning Beyond Latex and Gels

Treatment: Fulyzaq Approved for Diarrhea Relief

Cure: Embryo Survival Gene to Control HIV

Concerns: HIV-Positive Smokers Lose More Years

POZ Survey Says

Facing Discrimination

POZ Heroes

Not Lost in Translation

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

April / May 2013

HIV Docs Slow on Early Treatment

by Benjamin Ryan

A poll of 165 health care providers in Washington, DC, and the Bronx, New York, found that 95 percent “strongly agreed” or “agreed” that early use of antiretrovirals (ARVs) can lower HIV transmission, an assertion that has gained increased scientific proof of late.

Nevertheless, the poll found that only 56 percent of the clinicians said they favored starting ARVs for patients with CD4 levels less than 500, and just 14 percent encouraged patients to begin therapy immediately, regardless of CD4 counts. Three-quarters of the health care providers did recommend early therapy for HIV-positive patients in a relationship with someone uninfected with the virus, and 40 percent did so for those having unprotected sex with a partner of unknown HIV status.

The leader of the survey, Ann Kurth, PhD, professor and executive director at New York University College of Nursing Global, points out that the poll was taken before the famed HPTN 052 study showed that ARVs could cut transmission among heterosexual discordant couples by 96 percent and also before the U.S. Department of Health and Human Services adjusted its treatment guidelines to recommend ARV therapy to all people with HIV, strongly recommending that those in the 350 to 500 CD4 count range begin therapy.  Her team plans a follow-up poll.

“Clinicians will always try to decide if it’s the right thing for the client in front of them,” Kurth says of early treatment, “but I think increasingly it will become the norm to at least offer it to all persons.”

Search: HIV treatment, antiretrovirals, HIV care, HIV treatment guidelines, HIV transmission

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.